Literature DB >> 19604461

Bone health in systemic lupus erythematosus.

Pantelis Panopalis1, Jinoos Yazdany.   

Abstract

Patients with systemic lupus erythematosus (SLE) confront an increased risk of developing osteoporosis and fragility fractures. Traditional risk factors, such as smoking, advanced age, physical inactivity, and low weight, are partly responsible, but a number of lupus-specific risk factors may also play an important role. Chronic, systemic inflammation in patients with SLE has been proposed as a possible mechanism for osteoporosis development. Other potential risk factors include vitamin D deficiency due to sun avoidance, premature gonadal failure, and the chronic use of medications known to increase osteoporosis risk. Increased awareness of this potentially preventable condition is warranted, as early detection and treatment help optimize bone health and improve long-term outcomes in patients with SLE. This article presents recent epidemiologic data related to bone health in SLE and discusses preventative and therapeutic strategies.

Entities:  

Mesh:

Year:  2009        PMID: 19604461     DOI: 10.1007/s11926-009-0024-2

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  70 in total

1.  Osteopenia in young hypogonadal women with systemic lupus erythematosus receiving chronic steroid therapy: a randomized controlled trial comparing calcitriol and hormonal replacement therapy.

Authors:  A W Kung; T M Chan; C S Lau; R W Wong; S S Yeung
Journal:  Rheumatology (Oxford)       Date:  1999-12       Impact factor: 7.580

2.  Osteoporosis screening in systemic lupus erythematosus: impact of disease duration and organ damage.

Authors:  A Becker; R Fischer; W A Scherbaum; M Schneider
Journal:  Lupus       Date:  2001       Impact factor: 2.911

3.  Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group.

Authors:  C Roux; P Oriente; R Laan; R A Hughes; J Ittner; S Goemaere; O Di Munno; J M Pouillès; S Horlait; B Cortet
Journal:  J Clin Endocrinol Metab       Date:  1998-04       Impact factor: 5.958

4.  Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine.

Authors:  D Jardinet; C Lefèbvre; G Depresseux; M Lambert; J P Devogelaer; F A Houssiau
Journal:  Rheumatology (Oxford)       Date:  2000-04       Impact factor: 7.580

5.  Effect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy. A randomized, double blind, placebo controlled study.

Authors:  I Lambrinoudaki; D T Chan; C S Lau; R W Wong; S S Yeung; A W Kung
Journal:  J Rheumatol       Date:  2000-07       Impact factor: 4.666

6.  Bone mineral density, biochemical markers of bone turnover, and hormonal status in men with systemic lupus erythematosus.

Authors:  H P Bhattoa; E Kiss; P Bettembuk; A Balogh
Journal:  Rheumatol Int       Date:  2001-11       Impact factor: 2.631

7.  Prevention of corticosteroid-induced osteoporosis by alfacalcidol.

Authors:  P Lakatos; Z Nagy; L Kiss; C Horvath; I Takacs; J Foldes; G Speer; A Bossanyi
Journal:  Z Rheumatol       Date:  2000       Impact factor: 1.372

8.  Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus.

Authors:  C C Mok; A Mak; K M Ma
Journal:  Lupus       Date:  2005       Impact factor: 2.911

9.  Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.

Authors:  K G Saag; R Emkey; T J Schnitzer; J P Brown; F Hawkins; S Goemaere; G Thamsborg; U A Liberman; P D Delmas; M P Malice; M Czachur; A G Daifotis
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

10.  Self-reported fractures and associated factors in women with systemic lupus erythematosus.

Authors:  Chin Lee; Orit Almagor; Dorothy D Dunlop; Susan Manzi; Stewart Spies; Rosalind Ramsey-Goldman
Journal:  J Rheumatol       Date:  2007-09-01       Impact factor: 4.666

View more
  6 in total

1.  Significantly higher estimated 10-year probability of fracture in lupus patients with bone mineral density comparable to that of healthy individuals.

Authors:  Anselm Mak; Jia Qing Lim; Yang Liu; Alicia Ai-cia Cheak; Roger Chun-man Ho
Journal:  Rheumatol Int       Date:  2012-03-24       Impact factor: 2.631

Review 2.  Fracture risk and bone mineral density levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis.

Authors:  X Wang; S Yan; C Liu; Y Xu; L Wan; Y Wang; W Gao; S Meng; Y Liu; R Liu; D Xu
Journal:  Osteoporos Int       Date:  2016-01-11       Impact factor: 4.507

3.  Increased expression of human T-cell immunoglobulin- and mucin-domain-containing molecule-4 in peripheral blood mononuclear cells from patients with system lupus erythematosus.

Authors:  Peiqing Zhao; Liyun Xu; Piming Wang; Xiaohong Liang; Jianni Qi; Peng Liu; Chun Guo; Lining Zhang; Chunhong Ma; Lifen Gao
Journal:  Cell Mol Immunol       Date:  2010-02-08       Impact factor: 11.530

Review 4.  Pragmatic approaches to therapy for systemic lupus erythematosus.

Authors:  Wen Xiong; Robert G Lahita
Journal:  Nat Rev Rheumatol       Date:  2013-10-29       Impact factor: 20.543

5.  Inflammatory bone loss associated with MFG-E8 deficiency is rescued by teriparatide.

Authors:  Megan N Michalski; Anna L Seydel; Erica M Siismets; Laura E Zweifler; Amy J Koh; Benjamin P Sinder; J Ignacio Aguirre; Kamran Atabai; Hernan Roca; Laurie K McCauley
Journal:  FASEB J       Date:  2018-02-22       Impact factor: 5.191

6.  Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients.

Authors:  Diana Carmona-Fernandes; Maria José Santos; Inês Pedro Perpétuo; João Eurico Fonseca; Helena Canhão
Journal:  Arthritis Res Ther       Date:  2011-10-25       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.